Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is poised for success with a positive regulatory outlook for their pioneering OST-HER2 and OST-tADC drug technologies in the treatment of osteosarcoma and other solid tumors, supported by their recent regulatory designations and potential for accelerated approval pathways. With peak sales projections over $300M and strong potential for non-dilutive funding through Priority Review Voucher qualification, the company is well-positioned for commercial success. However, there are still risks to consider, such as clinical and regulatory risks, partnership and financial risks, and market share risk, which could impact their future prospects. Overall, the company presents a promising opportunity for investors in the biopharmaceutical sector.

Bears say

OS Therapies is facing significant risk factors, including clinical/regulatory, partnership, financial, commercial, legal and intellectual property, and market share risks. Their pipeline of product candidates, while promising, is still in preclinical development and has no revenue generation to support the company's operations. Additionally, with a minimal addressable market in the U.S. of only 108,758-190,899 HER II positive breast cancer patients, there may not be enough demand to drive profitability.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.